Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06037941 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

StatusRecruiting
PhaseNot applicable
Started2023-09-08
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Sep 2026 → Sep 2027
See other at-risk trials from Memorial Sloan Kettering Cancer Center

Amendment history

2026-09-25
Primary completion pushed: 2026-09 → 2027-09
Completion pushed: 2026-09 → 2027-09
2025-09-18
Study Status v4
Primary completion date2025-09→2026-09
Completion date2025-09→2026-09
2024-09-18
3 amendments v1-v3
3 re-verifications since 2024-04-30, no change to tracked fields
2023-09-08
Original filing
The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood.
Trial Details
NCT Number NCT06037941
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: UNIVERSITY CAMPUS BIO-MEDICO, ITALY
Conditions Malignant Pleural Mesothelioma
Enrollment 20 participants
Start Date 2023-09-08
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-09-24